Sanofi’s management has highlighted fitusiran, a potential competitor to Roche’s haemophilia A drug Hemlibra, as one of the most important drugs in its pipeline.

of adolescents and adults in the fitusiran group, compared to 17% with prior factor or BPA prophylaxis, said Sanofi. One issue dogging the programmes has been cases of blood clots in late-stage ...